RxDoctor Payments Data

Vithalbhai Dhaduk, MD

Neurology · Dunmore, PANPI 1023098902

Payments from drug & device makers

$172,655in general payments, 2019–2025

Across 1,611 payments — averaging $107.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$76K
  • Eisai Inc.$57K
  • Otsuka America Pharmaceutical, Inc.$7K
  • Pfizer$7K
  • SK Life Science, Inc.$5K
  • MDD US Operations, LLC$4K
  • plus $16K from 53 others

What the payments were for

  • Consulting fees$23,23513%
  • Speaking & faculty fees$120,52670%
  • Travel & lodging$4,7543%
  • Food & beverage$23,74914%
  • Education$3900%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)269$76,417
Eisai Inc.224$57,373
Otsuka America Pharmaceutical, Inc.17$6,680
Pfizer37$6,622
SK Life Science, Inc.28$4,690
MDD US Operations, LLC34$4,496
Genentech USA, Inc.9$1,840
Biogen77$1,295
AstraZeneca(2 entities)60$1,151
Neurocrine Biosciences, Inc.91$1,029
Supernus Pharmaceuticals, Inc.120$992
Sunovion Pharmaceuticals Inc.63$882
Novartis58$826
Lilly USA, LLC60$784
Teva Pharmaceuticals USA, Inc.52$708
EMD Serono, Inc.39$612
Amneal Pharmaceuticals LLC31$584
Amgen(2 entities)33$556
CSL Behring23$476
Kyowa Kirin, Inc.31$414
UCB, Inc.28$411
Johnson & Johnson29$369
Catalyst Pharmaceuticals, Inc.20$309
E.r. Squibb & Sons, L.L.C.15$285
Argenx US, Inc.14$239
Lundbeck LLC12$217
Avanir Pharmaceuticals, Inc.16$216
Biohaven Pharmaceuticals, Inc.13$210
Mallinckrodt Hospital Products Inc.9$173
Sanofi9$158
Takeda Pharmaceuticals U.S.A., Inc.11$156
Avion Pharmaceuticals7$129
Neurelis, Inc.7$120
Bristol Myers Squibb6$99
Vanda Pharmaceuticals Inc.5$96
Akcea Therapeutics, Inc.3$90
Acadia Pharmaceuticals Inc5$87
Grifols USA, LLC5$86
Livanova USA, Inc.2$80
TG Therapeutics, Inc.4$68
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)3$65
Abbott1$57
Sumitomo Pharma America, Inc.3$57
Axsome Therapeutics, Inc.3$56
Adamas Pharmaceuticals, Inc.4$53
Acorda Therapeutics, Inc4$52
Upsher-smith Laboratories LLC2$40
Impel Pharmaceuticals Inc.2$36
Alnylam Pharmaceuticals Inc.2$31
Sanofi-aventis U.S. LLC2$30
Ipsen Biopharmaceuticals, Inc1$24
Insightec,inc1$21
Averitas Pharma Inc.1$20
Life Molecular Imaging Ltd1$17
Validus Pharmaceuticals LLC1$15
Bayer1$14
Soleno Therapeutics, Inc.1$14
Tanabe Pharma America, Inc.1$14
Merz Pharmaceuticals, LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$172,655 in reported general payments places this provider in the 90th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$617,717
Medicare patients
665
Services billed
9,388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4637$554,085
OctagamImmun Globg(Igg)/Malt/Iga Ov5032$358,721
Rebif RebidoseInterferon Beta-1a/Albumin25$295,067
Avonex (4 Pack)Interferon Beta-1a27$233,298
Gamunex-CImmune Globul G/Gly/Iga Avg 4621$177,391
AustedoDeutetrabenazine19$167,722
Kesimpta PenOfatumumab11$94,551
AptiomEslicarbazepine Acetate43$88,702
CopaxoneGlatiramer Acetate12$66,345
Nurtec OdtRimegepant Sulfate42$54,332
FycompaPerampanel29$47,354
UbrelvyUbrogepant25$35,164
Aimovig AutoinjectorErenumab-Aooe28$21,886
RexultiBrexpiprazole16$21,698
Carbamazepine ErCarbamazepine157$18,605

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt$6,622$413,05474 claims
Teva Pharmaceuticals USA, Inc.Austedo, Copaxone$708$234,06631 claims
BiogenAvonex (4 Pack)$1,295$233,29827 claims
Grifols USA, LLCGamunex-C$86$177,39121 claims
Sunovion Pharmaceuticals Inc.Aptiom$882$88,70243 claims
Eisai Inc.Fycompa$57,373$47,35429 claims
AbbVieUbrelvy$76,417$35,16425 claims
Otsuka America Pharmaceutical, Inc.Rexulti$6,680$21,69816 claims
Amneal Pharmaceuticals LLCRytary$584$10,29012 claims
Neurocrine Biosciences, Inc.Ongentys$1,029$7,88312 claims
Upsher-smith Laboratories LLCTopiramate$40$4,627383 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Dunmore

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →